ライフサイエンスコーパス: serum cholesterol

1 ea nitrogen, proteinuria, serum albumin, and serum cholesterol).

2 yceride-lowering activity, T863 also lowered serum cholesterol.

3 henotype, and its inhibition decreases total serum cholesterol.

4 , body mass index, plasma ascorbic acid, and serum cholesterol.

5 is was also accompanied by reduced levels of serum cholesterol.

6 e at diagnosis, height, body mass index, and serum cholesterol.

7 rse relationship between thyroid hormone and serum cholesterol.

8 similar to those of blood pressure and total serum cholesterol.

9 r cardiovascular disease, including elevated serum cholesterol.

10 ny neurobehavioral effects of low or lowered serum cholesterol.

11 creased LDL receptor expression and elevated serum cholesterol.

12 n agonist to maintain bone density and lower serum cholesterol.

13 which is suppressed by atherogenic levels of serum cholesterol.

14 sity lipoprotein cholesterol (HDL-C) and low serum cholesterol.

15 ism is known to be associated with increased serum cholesterol.

16 a as Ldlr(+/+), SCD(bmt) mice despite higher serum cholesterol.

17 All groups had similar levels of serum cholesterol.

18 regulation and achieved stable reductions in serum cholesterol.

19 ccumulation of cholesterol in the liver than serum cholesterol.

20 digestion is considered a mechanism to lower serum-cholesterol.

21 eased systemic vascular resistance (by 11%), serum cholesterol (-20%), low-density lipoprotein choles

22 Elevated serum cholesterol accounts for a considerable proportion

23 These effects, such as a 50% decrease in serum cholesterol after 4 weeks of post-treatment with l

24 at BA synthesis contributes to the decreased serum cholesterol after BPD.

25 There was a nonsignificant increase in total serum cholesterol and a significant increase in serum tr

26 ibrosis, lowered platelet count, and lowered serum cholesterol and alanine aminotransferase (ALT) lev

27 However, studies of the relation between serum cholesterol and all-cause mortality in elderly peo

28 Statins reduce serum cholesterol and cardiovascular morbidity and morta

29 The association between decreased serum cholesterol and colorectal cancer risk suggests a

30 a1(-/-) mice, which were lean and had normal serum cholesterol and glucose levels.

31 acture, or other pathology, body mass index, serum cholesterol and glucose, liver function, blood pre

32 t beta-glucan (OBG) determines its effect on serum cholesterol and glycemic responses, but whether OB

33 nd IFN therapy are associated with decreased serum cholesterol and high cholesterol has been associat

34 ameters of susceptibility to T2DM, including serum cholesterol and high-density lipoprotein levels.

35 nal risk factors, such as blood pressure and serum cholesterol and homocysteine concentrations, and i

36 ges that included a significant reduction in serum cholesterol and increased fat accumulation in the

37 SIRT1 knockdown also decreased serum cholesterol and increased hepatic free fatty acid

38 This treatment reduced serum cholesterol and inhibited the development of ather

39 Serum cholesterol and insulin resistance were the only i

40 Although serum cholesterol and LDL predictably decreased signific

41 ABCA1-/- mice accompanied by a reduction in serum cholesterol and lipid deposition in various tissue

42 oved adherence and decreased levels of total serum cholesterol and low-density lipoprotein cholestero

43 Significant reductions in ApoB protein, serum cholesterol and low-density lipoprotein levels wer

44 he effects of dietary fat and cholesterol on serum cholesterol and on my activities that led to the p

45 that exposure to IH for five days increases serum cholesterol and PL levels, upregulates pathways of

46 We found a direct link between elevated serum cholesterol and reduced insulin secretion, with no

47 These mice also had reduced serum cholesterol and steatotic livers that was exacerba

48 switch to a control diet for 4 weeks reduced serum cholesterol and stopped lesion growth, and the hig

49 scous, gel-forming fibers, including reduced serum cholesterol and the attenuation of postprandial gl

50 uts and fatty fish in a healthy diet lowered serum cholesterol and triglyceride concentrations, respe

51 d in the liver and exhibited greatly reduced serum cholesterol and triglyceride levels and increased

52 Serum cholesterol and triglyceride levels did not differ

53 Increased serum cholesterol and triglyceride levels were observed,

54 C-III (apoA-I and apoC-III) mRNA levels and serum cholesterol and triglyceride levels, which was not

55 In addition, there was a decrease in serum cholesterol and triglyceride levels.

56 There was a significant decrease in serum cholesterol and triglyceride levels.

57 However, group 1 patients displayed higher serum cholesterol and triglyceride values, as well as lo

58 Lean 3KO mice had significantly lower serum cholesterol and triglycerides as well as improved

59 Constitutive differences in serum cholesterol and triglycerides in PPARalpha-null mi

60 For serum cholesterol and triglycerides, the achievable benc

61 f aortic total cholesterol, as well as lower serum cholesterol and triglycerides, when treated with a

62 mpacts over 14 days including high levels of serum cholesterols and persistent low serum iron level.

63 counseling to produce reductions in weight, serum cholesterol, and (along with antihypertensive medi

64 iNOS-/- mice have a propensity for increased serum cholesterol, and although controversial, several h

65 population, including body mass index (BMI), serum cholesterol, and blood pressure (BP), are also fou

66 ls for such traditional risk factors as BMI, serum cholesterol, and BP should be developed for CHF.

67 n of colorectal cancer risk with statin use, serum cholesterol, and change in cholesterol concentrati

68 pha-hydroxylase (CYP7A1) expression, reduced serum cholesterol, and high BA levels.

69 (subsp) cremoris on weight gain, liver fat, serum cholesterol, and insulin resistance in female mice

70 Vegans tend to be thinner, have lower serum cholesterol, and lower blood pressure, reducing th

71 se of aspirin after bypass, older age, lower serum cholesterol, and lowest Canadian Functional Class

72 s and had pleiotropic effects on liver mass, serum cholesterol, and serum alanine aminotransferase ac

73 vascular risk factors, notably hypertension, serum cholesterol, and smoking.

74 Serum, cholesterol, and meconium have been described as

75 ediary markers of risk that are analogous to serum cholesterol are less satisfactory and there are ne

76 Data for trends in serum cholesterol are needed to understand the effects o

77 k factors (heart rate, blood pressure, total serum cholesterol) assessed in 1987 among 693 Italian ma

78 new molecules for the control of cancer and serum cholesterol assisted by tools associated with rati

79 hat the decreased LDL receptor and increased serum cholesterol associated with hypothyroidism are sec

80 Pitavastatin did not reduce total serum cholesterol at any of the doses used.

81 ity, healthy diet, and an optimal profile of serum cholesterol, blood pressure, and glucose; 1 point

82 A (CoA) reductase inhibitors (statins) lower serum cholesterol but exhibit pleiotropic biological eff

83 ease, and a locus on chromosome 9 influenced serum cholesterol but not nephropathy.

84 en developed as food additives to help lower serum cholesterol but there is concern that these additi

85 ability is impaired in persons with elevated serum cholesterol, but can be improved by the administra

86 i-miR-122 TuD but not anti-let-7 TuD reduced serum cholesterol by >30% for 25 weeks in wild-type mice

87 Each episode of rejection increased serum cholesterol by 0.306 mmol/liter (0.258, 0.355) [me

88 of energy, a realistic target, would reduce serum cholesterol by 10% and mortality from ischemic hea

89 Atorvastatin lowered total serum cholesterol by about 1.3 mmol/L compared with plac

90 levels approximately 2-fold and lowers total serum cholesterol by up to 36%: this effect is not obser

91 ed accelerated atherosclerosis despite lower serum cholesterol compared with mice reconstituted with

92 unit increase, 1.61; 95% CI, 1.04-2.28), and serum cholesterol concentration (OR per 10-mg/dL [0.25-m

93 mission (HR 0.977 [95% CI 0.957-0.998]), and serum cholesterol concentration at presentation (HR 0.63

94 e association between dietary fat intake and serum cholesterol concentration in adults is unknown.

95 Healthy subjects with a mean (+/-SEM) serum cholesterol concentration of 5.10 +/- 0.18 mmol/L

96 waist-to-hip ratio, systolic blood pressure, serum cholesterol concentration, cigarette smoking, and

97 rated fat and cholesterol raises the average serum cholesterol concentration, leading to a higher ris

98 ently by age, sex, BMI, waist-hip ratio, and serum cholesterol concentration.

99 d pressure, waist and hip circumference, and serum cholesterol concentration; and overnight sleep mon

100 There is some evidence that lower serum cholesterol concentrations (as a surrogate for the

101 bjective was to examine the relation between serum cholesterol concentrations and performance in imme

102 IFN-gamma administration reduced serum cholesterol concentrations by 15% (P = 0.02).

103 mice exposed to constant light had increased serum cholesterol concentrations due to increased VLDL/L

104 Serum cholesterol concentrations have decreased in the U

105 as to quantify the effect of >/=3 g OBG/d on serum cholesterol concentrations in humans and investiga

106 examine the relation between fat intake and serum cholesterol concentrations in men and women whose

107 f high intakes of total and saturated fat on serum cholesterol concentrations in men may be confined

108 turated fat intakes were not associated with serum cholesterol concentrations in men or women.

109 IL-18 administration did not affect serum cholesterol concentrations or lipoprotein-choleste

110 inal assessment of changes in both lipid and serum cholesterol concentrations over 20 years, and comp

111 Lipid and serum cholesterol concentrations were measured in 3572 J

112 The number of complications and serum cholesterol concentrations were predictive for mor

113 h in saturated fat and may, therefore, raise serum cholesterol concentrations, but beneficial effects

114 , there was no significant difference in the serum cholesterol concentrations, but there were signifi

115 y important roles in reducing intestinal and serum cholesterol concentrations, directly impacting hum

116 Despite the decrease in serum cholesterol concentrations, IFN-gamma injections s

117 for intestinal absorption and thereby lower serum cholesterol concentrations.

118 To determine whether higher levels of serum cholesterol could enhance the organ burdens of B.

119 ent risk factor among men with low levels of serum cholesterol, data on 25-year coronary, cardiovascu

120 Total serum cholesterol decreased after PEBD in ALGS patients

121 After 8 months of regression diet (n=9), serum cholesterol decreased to normal, and O2*- levels (

122 The studies on serum cholesterol defined the role of the various classe

123 mg/dL; 95% CI, -2.0 to 14.3 mg/dL; P = .14), serum cholesterol (Delta, -0.6 mg/dL; 95% CI, -5.1 to 4.

124 In contrast, elevated serum cholesterol did not lead to an increase in the spi

125 y was to investigate links between childhood serum cholesterol ester fatty acid (CEFA) proportions an

126 suggest that fat quality as reflected in the serum cholesterol ester fraction in childhood is indepen

127 Serum cholesterol ester is the most suitable serum fract

128 Serum cholesterol ester SFA and PUFA associations were s

129 PUFAs in serum cholesterol esters were measured at baseline in 60

130 Established guidelines for testing of total serum cholesterol for hypercholesterolemia are appropria

131 Estimates of the mean reduction in serum cholesterol from baseline between the OBG and cont

132 se subjects also had fasting blood drawn for serum cholesterol, glucose, and a number of novel biomar

133 e in the prevalence of hypercholesterolemia (serum cholesterol > 200 mg/dL) between the groups.

134 Raised serum cholesterol (>5.0 mmol/L) was found in 48 (44%) pa

135 ter BPD, insulin sensitivity had doubled and serum cholesterol had halved.

136 Statins, used to lower serum cholesterol, have immune-modulating activities.

137 Levels of serum cholesterol, high-density lipoprotein cholesterol

138 ions between contemporaneously assayed total serum cholesterol, high-density lipoprotein cholesterol

139 race/ethnicity, education, body mass index, serum cholesterol, hypertension, and NHANES phase (or cy

140 itional CVD risk factors including age, sex, serum cholesterol, hypertension, diabetes, and smoking.

141 The data show that total serum cholesterol in Japanese and Spanish children recen

142 Serum cholesterol in Japanese children was predicted to

143 els of LDL-cholesterol and potently reducing serum cholesterol in mice, and selectively reduce LDL-ch

144 sed hepatic cholesterol content, and lowered serum cholesterol in mice.

145 acceptance of reliable methods for measuring serum cholesterol in nonmedical settings may eventually

146 Hypercholesterolemia, high serum cholesterol in the form of LDL, is a major risk fa

147 e been extended to children, but the role of serum cholesterol in the neurodevelopment of children is

148 he 3 neurobehavioral tests were unrelated to serum cholesterol in women.

149 and 4.64 (95% CI: 1.93, 7.36) mmol/L higher serum cholesterol in women.

150 Multiple risk factors contribute to elevated serum cholesterol including the use of certain immunosup

151 Serum cholesterol increased from 122+/-7 to 550+/-59 mg/

152 s4743771 is a major determinant of undesired serum cholesterol increases in rosi-treated diabetics.

153 changes were not explained by alterations in serum cholesterol, inflammatory mediators or infiltrates

154 A high level of serum cholesterol is a major cause of atherosclerosis.

155 The lowering of serum cholesterol is increasingly recognised as essentia

156 e adaptive immune response and that elevated serum cholesterol is responsible for this effect.

157 Serum cholesterol, LDL levels and triglycerides decrease

158 Plaques were stabilized by reducing serum cholesterol leading to several favorable pathobiol

159 High-fat diet-mediated increases in serum cholesterol, leptin, glucose, and fat accumulation

160 Those with a serum cholesterol level >200 mg/dL had a rate of AVA red

161 all organs examined) mouse models, a reduced serum cholesterol level and an induction of hepatic P450

162 he curvilinear, or log-linear, model between serum cholesterol level and risk for coronary artery dis

163 Recent epidemiologic data show that low serum cholesterol level as well as statin use is associa

164 Significant differences in serum cholesterol level between groups were achieved and

165 CIH caused a greater elevation in serum cholesterol level in ApoE-p50-DKO than in ApoE-KO

166 for middle-aged cohorts (aged 40-64 years), serum cholesterol level is known to be an established ma

167 baseline, 36.7% of patients achieved a total serum cholesterol level less than 5.0 mmol/L, compared w

168 ected 3 cohorts of younger men with baseline serum cholesterol level measurements and no history of d

169 g role, predisposing CHF patients with a low serum cholesterol level to inflammatory consequences of

170 nstrate a continuous, graded relationship of serum cholesterol level to long-term risk of CHD, CVD, a

171 /dL (1.0-mmol/L) increment in baseline total serum cholesterol level was associated with a decreased

172 In contrast, serum cholesterol level was associated with an increased

173 Average serum cholesterol level was lower in the presence of inf

174 ciated with higher risk (P = 0.007), whereas serum cholesterol level was not associated with risk of

175 Serum cholesterol level was significantly (P=0.03) lower

176 nfidence interval, 2.6 to 8.7), and a higher serum cholesterol level were independently related to th

177 es of systolic and diastolic blood pressure, serum cholesterol level, body mass index, presence of di

178 th colorectal cancer, prior cholecystectomy, serum cholesterol level, physical activity, smoking, alc

179 24-hour urinary protein excretion, serum cholesterol level, serum albumin level, creatinine

180 L), and liver for intrahepatic lipids (IHL), serum cholesterol level, serum triglyceride level, and m

181 All major risk factors-age, serum cholesterol level, systolic blood pressure, and ci

182 ng status, history of myocardial infarction, serum cholesterol level, urinalysis proteinuria, urinaly

183 body mass index, diabetes, hypertension, and serum cholesterol level.

184 lism, deliver adequate dialysis, and control serum cholesterol level.

185 r body mass index, prior cholecystectomy, or serum cholesterol level.

186 ion of RALY alters hepatic lipid content and serum cholesterol level.

187 obese, and 23 patients (27.4%) had elevated serum cholesterol levels (> or =240 mg/dl, 6.22 mmol/L),

188 Men in all 3 cohorts with unfavorable serum cholesterol levels (200-239 mg/dL [5.17-6.18 mmol/

189 Whether elevated serum cholesterol levels act as such a factor is unknown

190 Serum cholesterol levels after 32 weeks were 809+/-40 mg

191 n the nanomolar range that effectively lower serum cholesterol levels and are widely prescribed in th

192 n, lowered serum triglyceride, and increased serum cholesterol levels and attenuated dietary fatty ac

193 -dependent LDLR endocytosis promote elevated serum cholesterol levels and can lead to atherosclerosis

194 Because of the strong association between serum cholesterol levels and coronary artery disease, in

195 Serum cholesterol levels and de novo lipid synthesis wer

196 Total serum cholesterol levels and extent and phenotype of ath

197 deletion had no effect on brain and reduced serum cholesterol levels and lovastatin (1.5 mg/kg, twic

198 These mice have significantly different serum cholesterol levels and steady-state brain APOE lev

199 This was related to increased serum cholesterol levels and subsequent hyperlipidemia-i

200 Serum cholesterol levels are some of the most accurate l

201 in cholesterol transport that result in high serum cholesterol levels can affect the pathogenicity of

202 nic exposure exerted opposite effects on the serum cholesterol levels in conventional and AB-treated

203 nventional and AB-treated mice, i.e., higher serum cholesterol levels in conventional mice but lower

204 Treatment with simvastatin had no effect on serum cholesterol levels in either normal or hypercholes

205 cal data also suggest cholesterol intake and serum cholesterol levels may be linked with the developm

206 s, and that the pharmacological reduction of serum cholesterol levels may retard prostate cancer grow

207 For men with serum cholesterol levels of 240 mg/dL or greater (>/=6.2

208 The serum cholesterol levels of the ApoE(-) mice were signif

209 ies report an association between cancer and serum cholesterol levels or statin use, while others sug

210 he underlying mechanism of how TFA modulates serum cholesterol levels remains elusive.

211 The serum cholesterol levels rose in all mice fed this diet.

212 n the cuprizone model, acute disease reduces serum cholesterol levels that can be restored by dietary

213 68E-17), which coincides with a tendency for serum cholesterol levels to increase in WD-fed rats (p =

214 As a secondary measure, serum cholesterol levels were assessed.

215 Serum cholesterol levels were determined using a standar

216 Total serum cholesterol levels were elevated similarly in the

217 Nevertheless, no differences in serum cholesterol levels were observed between the H. fe

218 Serum cholesterol levels were unaffected by simvastatin

219 e, estimated glomerular filtration rate, and serum cholesterol levels).

220 d PCSK9 is able to regulate LDL receptor and serum cholesterol levels, although somewhat less efficie

221 elop less liver fat and inflammation, reduce serum cholesterol levels, and increase glucose tolerance

222 and CVD death for younger men with elevated serum cholesterol levels, and longer estimated life expe

223 ed PCSK9 resulted in significantly increased serum cholesterol levels, approaching the increase by in

224 ns preserve endothelial function by reducing serum cholesterol levels, it has been suggested they may

225 Serum cholesterol levels, low-density lipoprotein choles

226 ic plaque remained after accounting for age, serum cholesterol levels, smoking history, and hypertens

227 ses independent of their effects on lowering serum cholesterol levels.

228 amer was found to be effective in decreasing serum cholesterol levels.

229 +antioxidant groups had similar increases in serum cholesterol levels.

230 ient decrease and AAV2-LDLR failed to reduce serum cholesterol levels.

231 channels in the kidney, as well as increased serum cholesterol levels.

232 diovascular diseases in populations with low serum cholesterol levels.

233 prevail for men with lower as well as higher serum cholesterol levels.

234 had reduced liver lipid levels but increased serum cholesterol levels.

235 cient mice, despite causing relatively lower serum cholesterol levels.

236 y by drugs in the clinical treatment of high serum cholesterol levels.

237 fe expectancy for younger men with favorable serum cholesterol levels.

238 eraction with SREBP-2 and reduction of liver/serum cholesterol levels.

239 eceptor (LDLR) degradation, thus influencing serum cholesterol levels.

240 on a high fat diet and manifest half-normal serum cholesterol levels.

241 isoforms can differentially influence total serum cholesterol levels; therefore, APOE has been linke

242 ed toxicities-myelosuppression and increased serum cholesterol/low-density lipoprotein cholesterol-oc

243 e chronic inflammation, in addition to their serum cholesterol-lowering effects, we hypothesized that

244 diet, body mass index <25 kg/m(2), untreated serum cholesterol <200 mg/dL, untreated blood pressure <

245 urrently in two units without the algorithm, serum cholesterol measurements decreased from 5.57 mmol/

246 utamine, tyrosine and isoleucine, along with serum cholesterol measures and atherogenic lipoproteins.

247 ween memory or coding speed and the selected serum cholesterol measures in men, and the scores of the

248 vastatin had a direct effect (independent of serum cholesterol) on both the EDSS, which explained 69%

249 t rest was not significantly correlated with serum cholesterol or insulin resistance (estimated from

250 ined whether there is an association between serum cholesterol or insulin resistance and change in bl

251 s in the BM of recipients but not with total serum cholesterol or percentage of BM-CD31(+)/CD45(low)

252 None of the diets altered the serum cholesterol or triglyceride levels in these mice;

253 rmalities but not with higher blood glucose, serum cholesterol, or serum homocysteine levels.

254 protocol to assess surfactant inhibition by serum, cholesterol, or meconium in the captive bubble su

255 ) improves insulin sensitivity and decreases serum cholesterol out of proportion with weight loss.

256 ggulipid did not appear to improve levels of serum cholesterol over the short term in this population

257 .5%; or reoperative CEA, 3.2%) with elevated serum cholesterol (P < 0.017) correlating with early res

258 bservations coincided with reduced levels of serum cholesterol particularly LDL cholesterol observed

259 cant effect of vitamin D3 supplementation on serum cholesterol profile or surrogate biomarkers of cho

260 hesis, consistent with the lack of effect on serum cholesterol profile.

261 , p < 0.001), BMI (r = 0.133, p = 0.001) and serum cholesterol (r = 0.094, p = 0.003).

262 pressure during exercise was correlated with serum cholesterol (R>0.47, P<0.0001 for each workload) a

263 mass index, baseline serum glucose, baseline serum cholesterol, recipient age and treated rejection,

264 an exert beneficial effects independently of serum cholesterol reduction by increasing the bioavailab

265 The Pro12Ala polymorphism affected the serum cholesterol response to n-3 PUFA treatment.

266 ed CVD risk factors (high blood pressure and serum cholesterol, smoking, and high blood glucose), hig

267 iovascular risk is inversely correlated with serum cholesterol, suggesting that a process other than

268 l studies revealed that mean levels of total serum cholesterol (TC), low-density lipoproteins (LDLs),

269 ame magnitude as those for men with elevated serum cholesterol, that is, 200-239 and 240 mg/dl.

270 imary mechanism of action is the lowering of serum cholesterol through inhibiting hepatic cholesterol

271 d equation was used to relate differences in serum cholesterol to dietary fat intake.

272 n achieved with this population by mapping a serum cholesterol trait to a 2-Mb region on chromosome 3

273 oe (-/-) mice displayed reduced body weight, serum cholesterol, triglycerides and free fatty acids, s

274 y to the identification of many people whose serum cholesterol, triglycerides, and HDL-cholesterol re

275 on model incorporating age, body mass index, serum cholesterol, triglycerides, HDL cholesterol, insul

276 There was no significant difference in serum cholesterol, triglycerides, low-density lipoprotei

277 rtening, left ventricular ejection fraction, serum cholesterol, uric acid, mixed venous saturation, a

278 sis of dyslipidemia was established when the serum cholesterol value (CHO) was more than 240 mg/dL or

279 ed to improve bone mineral density and lower serum cholesterol values compared with older SERMs in sm

280 or the ratio of pleural fluid cholesterol to serum cholesterol was greater than 0.3 (LR, 14; 95% CI,

281 Increased serum cholesterol was independently associated with decr

282 Serum cholesterol was measured by use of standard method

283 7-0.91); the association was only present if serum cholesterol was measured near the cancer diagnosis

284 Serum cholesterol was reduced with pNAPE-EcN, but athero

285 Serum cholesterol was similarly elevated in HC and HC+PS

286 Serum cholesterol was unchanged.

287 PCSK9 and LDLR and the resultant effects on serum cholesterol, we produced transgenic mice expressin

288 Diabetes mellitus prevalence and mean serum cholesterol were each associated with greater rela

289 tions of hemoglobin, serum triglyceride, and serum cholesterol were found between the 2 groups.

290 deficient mice that produce large amounts of serum cholesterol were infected with both spirochetes.

291 Previous analyses of trends in serum cholesterol were limited to a few countries, with

292 level higher than 10 mIU/L to elevations in serum cholesterol were rated as fair but data relating t

293 istory, history of diabetes mellitus, and/or serum cholesterol were used to calculate hazard ratios (

294 Obesity-induced changes in serum-cholesterol were blocked in PDE3B(-/-)mice.

295 /-) mice indicated a significant decrease in serum cholesterol when compared with wild-type mice.

296 a significant long-lasting decrease in total serum cholesterol whereas AAV9-LDLR resulted only in a t

297 s shown to be downregulated by elevations in serum cholesterol, which also resulted in invasion of th

298 Attempts at reducing serum cholesterol with different strategies in the past

299 roduces efficient genome editing and reduced serum cholesterol with exceptionally high specificity.

300 transporter (ASBT) inhibitor would lower the serum cholesterol without the potential systemic side ef